HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Borja, Mark S ^a   Zhao, Lei ^b   Hammerson, Bradley ^c   Tang, Chongren ^d   Yang, Richard ^b   Carson, Nancy ^b   Fernando, Gayani ^b   Liu, Xiaoqin ^b   Budamagunta, Madhu S ^e   Genest, Jacques ^f   Shearer, Gregory C ^g,h   Duclos, Franck ^b   Oda, Michael N ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Accent Assays Inc   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ROYAL VICTORIA HOSPITAL   (Canada)

^g SANFORD RESEARCH   (United States)

^h UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; ELECTRON SPIN RESONANCE; HIGH DENSITY LIPOPROTEIN APOLIPOPROTEIN A1 EXCHANGE; HUMAN; LIPID DIET; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PROTEIN ISOLATION; PROTEIN TRANSPORT; RABBIT; RAPID TEST; RISK REDUCTION;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROGEN PEROXIDE; LIPOPROTEINS, HDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDANTS; OXIDATION-REDUCTION; PEROXIDASE; PROTEIN BINDING; RABBITS; RISK FACTORS; YOUNG ADULT;

EID: 84883180605     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071541     Document Type: Article

References (81)

1. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM, (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8: 222-232.
2. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, et al. (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256: 2835-2838.
3. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR, (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62: 707-714.
4. Eren E, Yilmaz N, Aydin O, (2012) High Density Lipoprotein and it's Dysfunction. Open Biochem J 6: 78-93.
5. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD, (2012) High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 32: 2813-2820.
6. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, et al. (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96: 2758-2767.
7. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, et al. (2010) Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121: 110-122.
8. Annema W, Nijstad N, Tolle M, de Boer JF, Buijs RV, et al. (2010) Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J Lipid Res 51: 743-754.
9. van der Westhuyzen DR, de Beer FC, Webb NR, (2007) HDL cholesterol transport during inflammation. Curr Opin Lipidol 18: 147-151.
10. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, et al. (2009) Inflammation impairs reverse cholesterol transport in vivo. Circulation 119: 1135-1145.
11. Rye KA, Barter PJ, (2004) Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 24: 421-428.
12. Liang HQ, Rye KA, Barter PJ, (1995) Cycling of apolipoprotein A-I between lipid-associated and lipid-free pools. Biochim Biophys Acta 1257: 31-37.
13. Liang HQ, Rye KA, Barter PJ, (1996) Remodelling of reconstituted high density lipoproteins by lecithin: cholesterol acyltransferase. J Lipid Res 37: 1962-1970.
14. Rye KA, Hime NJ, Barter PJ, (1997) Evidence that cholesteryl ester transfer protein-mediated reductions in reconstituted high density lipoprotein size involve particle fusion. J Biol Chem 272: 3953-3960.
15. Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm C, (1996) The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J 313 (Pt 1):: 275-282.
16. Ryan RO, Yokoyama S, Liu H, Czarnecka H, Oikawa K, et al. (1992) Human apolipoprotein A-I liberated from high-density lipoprotein without denaturation. Biochemistry 31: 4509-4514.
17. Nijstad N, Wiersma H, Gautier T, van der Giet M, Maugeais C, et al. (2009) Scavenger receptor BI-mediated selective uptake is required for the remodeling of high density lipoprotein by endothelial lipase. J Biol Chem 284: 6093-6100.
18. Yasuda T, Ishida T, Rader DJ, (2010) Update on the role of endothelial lipase in high-density lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 74: 2263-2270.
19. Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, et al. (2009) Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res 50: 894-907.
20. Mulya A, Lee JY, Gebre AK, Thomas MJ, Colvin PL, et al. (2007) Minimal lipidation of pre-beta HDL by ABCA1 results in reduced ability to interact with ABCA1. Arterioscler Thromb Vasc Biol 27: 1828-1836.
21. Wang X, Rader DJ, (2007) Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol 22: 368-372.
22. Okuhira K, Tsujita M, Yamauchi Y, Abe-Dohmae S, Kato K, et al. (2004) Potential involvement of dissociated apoA-I in the ABCA1-dependent cellular lipid release by HDL. J Lipid Res 45: 645-652.
23. Curtiss LK, Valenta DT, Hime NJ, Rye KA, (2006) What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol 26: 12-19.
24. Pownall HJ, Hosken BD, Gillard BK, Higgins CL, Lin HY, et al. (2007) Speciation of human plasma high-density lipoprotein (HDL): HDL stability and apolipoprotein A-I partitioning. Biochemistry 46: 7449-7459.
25. Cavigiolio G, Geier EG, Shao B, Heinecke JW, Oda MN, (2010) Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J Biol Chem 285: 18847-18857.
26. Smith JD, (2010) Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 30: 151-155.
27. Nobecourt E, Tabet F, Lambert G, Puranik R, Bao S, et al. (2010) Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 30: 766-772.
28. Pu LJ, Lu L, Zhang RY, Du R, Shen Y, et al. (2012) Glycation of Apoprotein A-I Is Associated With Coronary Artery Plaque Progression in Type 2 Diabetic Patients. Diabetes Care.
29. Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, et al. (2010) Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem 285: 18473-18484.
30. Shao B, Fu X, McDonald TO, Green PS, Uchida K, et al. (2005) Acrolein impairs ATP binding cassette transporter A1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I. J Biol Chem 280: 36386-36396.
31. Shao B, Oda MN, Oram JF, Heinecke JW, (2006) Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 21: 322-328.
32. Vaisar T, Shao B, Green PS, Oda MN, Oram JF, et al. (2007) Myeloperoxidase and inflammatory proteins: pathways for generating dysfunctional high-density lipoprotein in humans. Curr Atheroscler Rep 9: 417-424.
33. Shao B, Oda MN, Oram JF, Heinecke JW, (2010) Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 23: 447-454.
34. Shao B, Pennathur S, Heinecke JW, (2012) Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 287: 6375-6386.
35. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA, et al. (2009) Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 284: 30825-30835.
36. Nicholls SJ, Zheng L, Hazen SL, (2005) Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 15: 212-219.
37. Heinecke JW, (2003) Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 91: 12A-16A.
38. Ambrose JA, Barua RS, (2004) The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43: 1731-1737.
39. Wang Y, Rosen H, Madtes DK, Shao B, Martin TR, et al. (2007) Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation. J Biol Chem 282: 31826-31834.
40. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, et al. (2004) Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114: 529-541.
41. Peng DQ, Wu Z, Brubaker G, Zheng L, Settle M, et al. (2005) Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities. J Biol Chem 280: 33775-33784.
42. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, et al. (2004) Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 279: 42977-42983.
43. Shao B, Bergt C, Fu X, Green P, Voss JC, et al. (2005) Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem 280: 5983-5993.
44. Shao B, Oda MN, Bergt C, Fu X, Green PS, et al. (2006) Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem 281: 9001-9004.
45. Shao B, Cavigiolio G, Brot N, Oda MN, Heinecke JW, (2008) Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A 105: 12224-12229.
46. Hubbell WL, Cafiso DS, Altenbach C, (2000) Identifying conformational changes with site-directed spin labeling. Nat Struct Biol 7: 735-739.
47. Oda MN, Forte TM, Ryan RO, Voss JC, (2003) The C-terminal domain of apolipoprotein A-I contains a lipid-sensitive conformational trigger. Nat Struct Biol 10: 455-460.
48. Shearer GC, Pottala JV, Hansen SN, Brandenburg V, Harris WS, (2012) Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. J Lipid Res 53: 2429-2435.
49. Martin DD, Budamagunta MS, Ryan RO, Voss JC, Oda MN, (2006) Apolipoprotein A-I assumes a "looped belt" conformation on reconstituted high density lipoprotein. J Biol Chem 281: 20418-20426.
50. Cavigiolio G, Shao B, Geier EG, Ren G, Heinecke JW, et al. (2008) The interplay between size, morphology, stability, and functionality of high-density lipoprotein subclasses. Biochemistry 47: 4770-4779.
51. Oda MN, Bielicki JK, Berger T, Forte TM, (2001) Cysteine substitutions in apolipoprotein A-I primary structure modulate paraoxonase activity. Biochemistry 40: 1710-1718.
52. Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, et al. (2005) Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 280: 38-47.
53. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, et al. (2010) The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 30: 796-801.
54. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127-135.
55. Shao B, Tang C, Heinecke JW, Oram JF, (2010) Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res 51: 1849-1858.
56. Hoofnagle AN, Wu M, Gosmanova AK, Becker JO, Wijsman EM, et al. (2010) Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arterioscler Thromb Vasc Biol 30: 2528-2534.
57. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, et al. (2005) Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 46: 2246-2253.
58. Mulya A, Lee JY, Gebre AK, Boudyguina EY, Chung SK, et al. (2008) Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res 49: 2390-2401.
59. Lagerstedt JO, Budamagunta MS, Oda MN, Voss JC, (2007) Electron paramagnetic resonance spectroscopy of site-directed spin labels reveals the structural heterogeneity in the N-terminal domain of apoA-I in solution. J Biol Chem 282: 9143-9149.
60. Lagerstedt JO, Cavigiolio G, Budamagunta MS, Pagani I, Voss JC, et al. (2011) Structure of apolipoprotein A-I N terminus on nascent high density lipoproteins. J Biol Chem 286: 2966-2975.
61. Lagerstedt JO, Budamagunta MS, Liu GS, DeValle NC, Voss JC, et al. (2012) The "beta-clasp" model of apolipoprotein A-I-a lipid-free solution structure determined by electron paramagnetic resonance spectroscopy. Biochim Biophys Acta 1821: 448-455.
62. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, et al. (2004) The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 101: 13032-13037.
63. Mikkola TS, Anthony MS, Clarkson TB, St Clair RW, (2003) Serum cholesterol efflux potential is an independent predictor of coronary artery atherosclerosis. Atherosclerosis 170: 31-38.
64. Tang C, Vaughan AM, Oram JF, (2004) Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem 279: 7622-7628.
65. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, et al. (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24: 2181-2187.
66. Tsai MY, Johnson C, Kao WH, Sharrett AR, Arends VL, et al. (2008) Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 200: 359-367.
67. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, et al. (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294: 2437-2445.
68. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, et al. (2008) High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 51: 634-642.
69. Gursky O, (2005) Apolipoprotein structure and dynamics. Curr Opin Lipidol 16: 287-294.
70. Pownall HJ, Ehnholm C, (2006) The unique role of apolipoprotein A-I in HDL remodeling and metabolism. Curr Opin Lipidol 17: 209-213.
71. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, et al. (2000) Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343: 1148-1155.
72. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH, (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979.
73. Kuller LH, Tracy RP, Shaten J, Meilahn EN, (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144: 537-547.
74. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, et al. (1999) C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242.
75. Daugherty A, Dunn JL, Rateri DL, Heinecke JW, (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437-444.
76. Hazen SL, Gaut JP, Crowley JR, Hsu FF, Heinecke JW, (2000) Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions. Biochem J 352 Pt 3: 693-699.
77. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, et al. (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286: 2136-2142.
78. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, et al. (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349: 1595-1604.
79. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. (2005) The double jeopardy of HDL. Ann Med 37: 173-178.
80. Qiao Q, (2006) Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 49: 2837-2846.
81. Bittner V, Simon JA, Fong J, Blumenthal RS, Newby K, et al. (2000) Correlates of high HDL cholesterol among women with coronary heart disease. Am Heart J 139: 288-296.